Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume -, Issue -, Pages 106002802211468
Publisher
SAGE Publications
Online
2023-01-14
DOI
10.1177/10600280221146878
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
- (2021) Briana M. Choi et al. JOURNAL OF MEDICAL ECONOMICS
- Systemic Therapy for Melanoma: ASCO Guideline
- (2020) Rahul Seth et al. JOURNAL OF CLINICAL ONCOLOGY
- Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing
- (2020) Nimer S. Alkhatib et al. JOURNAL OF MEDICAL ECONOMICS
- The six Delta platform for outcome-based contracting for pharmaceuticals
- (2020) Nimer S. Alkhatib et al. JOURNAL OF MEDICAL ECONOMICS
- Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
- (2019) F. Consoli et al. Clinical & Translational Oncology
- Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review
- (2019) Claire Gorry et al. VALUE IN HEALTH
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
- (2014) Anthony J Hatswell et al. Health and Quality of Life Outcomes
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
- (2014) Patti Curl et al. PLoS One
- Melanoma Treatment Costs
- (2012) Gery P. Guy et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Elicitation of health state utilities in neuroendocrine tumours
- (2012) P. Swinburn et al. JOURNAL OF MEDICAL ECONOMICS
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now